Travere Therapeutics Financials
| TVTX Stock | USD 18.81 0.11 0.59% |
| Current Value | Last Year | Change From Last Year | 10 Year Trend | ||||||
|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 1.99 | 3.4668 |
|
|
The essential information of the day-to-day investment outlook for Travere Therapeutics includes many different criteria found on its balance sheet. An individual investor should monitor Travere Therapeutics' cash flow, debt, and profitability to accurately make informed decisions on whether to invest in Travere Therapeutics.
Net Income |
|
Travere | Select Account or Indicator |
Understanding current and past Travere Therapeutics Financials, including the trends in assets, liabilities, equity and income are directly related to making proper and timely investing decisions. All of Travere Therapeutics' financial statements are interrelated, with each one affecting the others. For example, an increase in Travere Therapeutics' assets may result in an increase in income on the income statement.
Please note, the imprecision that can be found in Travere Therapeutics' accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of Travere Therapeutics. Check Travere Therapeutics' Beneish M Score to see the likelihood of Travere Therapeutics' management manipulating its earnings.
Travere Therapeutics Stock Summary
Travere Therapeutics competes with Tff Pharmaceuticals, Eliem Therapeutics, Inhibrx, and Enliven Therapeutics. Travere Therapeutics, Inc., a biopharmaceutical company, focuses on the identification, development, commercialization, and delivering of therapies for the treatment of rare diseases. Travere Therapeutics, Inc. was incorporated in 2008 and is headquartered in San Diego, California. Travere Therapeutics operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 310 people.Specialization | Health Care, Pharmaceuticals, Biotechnology & Life Sciences |
| Instrument | USA Stock View All |
| Exchange | NASDAQ Exchange |
| ISIN | US89422G1076 |
| CUSIP | 89422G107 761299106 250392305 |
| Location | California; U.S.A |
| Business Address | 3611 Valley Centre |
| Sector | Biotechnology |
| Industry | Health Care |
| Benchmark | Dow Jones Industrial |
| Website | www.travere.com |
| Phone | 888 969 7879 |
| Currency | USD - US Dollar |
Travere Therapeutics Key Financial Ratios
| Return On Equity | -2.8 | ||||
| Profit Margin | (1.73) % | ||||
| Operating Margin | (0.89) % | ||||
| Price To Sales | 8.05 X | ||||
| Revenue | 145.24 M |
Travere Therapeutics Key Balance Sheet Accounts
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Total Assets | 604.8M | 607.4M | 776.6M | 672.6M | 788.9M | 461.7M | |
| Other Current Liab | 68.8M | 80.5M | 84.9M | 104.0M | 119.3M | 60.3M | |
| Net Debt | 142.4M | 130.6M | 96.2M | 345.8M | 346.6M | 363.9M | |
| Retained Earnings | (416.4M) | (585.9M) | (766.0M) | (1.0B) | (1.1B) | (1.1B) | |
| Accounts Payable | 26.6M | 12.1M | 15.1M | 17.3M | 41.7M | 43.8M | |
| Cash | 62.4M | 84.8M | 165.8M | 61.7M | 58.2M | 58.0M | |
| Total Liab | 383.6M | 396.2M | 474.5M | 629.7M | 588.1M | 617.5M | |
| Total Current Assets | 429.1M | 410.4M | 582.8M | 486.4M | 616.8M | 316.3M | |
| Short Term Debt | 2.6M | 357K | 7.8M | 8.9M | 9.8M | 9.4M | |
| Other Current Assets | 6.4M | 8.1M | 6.7M | 15.0M | 19.3M | 20.3M | |
| Intangible Assets | 157.2M | 153.2M | 148.4M | 145.0M | 103.7M | 140.4M | |
| Net Receivables | 18.0M | 33.1M | 15.9M | 16.6M | 21.2M | 21.3M | |
| Inventory | 6.1M | 7.6M | 7.3M | 6.9M | 9.4M | 6.0M | |
| Other Liab | 83.3M | 59.9M | 92.4M | 84.5M | 76.1M | 67.7M | |
| Net Tangible Assets | 63.1M | 57.1M | 153.7M | (102.2M) | (92.0M) | (87.4M) | |
| Other Assets | 14.7M | 7.8M | 11.1M | 36K | 32.4K | 30.8K | |
| Long Term Debt | 204.9M | 215.3M | 226.6M | 375.5M | 377.3M | 257.7M | |
| Net Invested Capital | 426.1M | 426.6M | 528.7M | 418.4M | 578.1M | 511.0M | |
| Net Working Capital | 333.6M | 317.7M | 458.7M | 344.3M | 438.9M | 396.7M |
Travere Therapeutics Key Income Statement Accounts
An income statement is very similar to a cash flow statement, but instead of showing net revenue minus expenses, it only includes earnings before interest and taxes (EBIT). This number does not have all of the same line items that are on a cash flow statement, but it leaves out non-cash expenses like depreciation and amortization. For example, if you bought $100 worth of goods from Walmart (WMT) using your debit card that has an interest rate of 20%, then paid off the balance at the end of the month with a credit card that charges 30% interest, you would have an income statement showing EBIT of $80 because your expenses are lower than the amount that went into your pocket.
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Interest Expense | 18.8M | 19.1M | 20.1M | 11.3M | 11.3M | 16.4M | |
| Operating Income | (99.8M) | (75.4M) | (139.5M) | (251.6M) | (376.7M) | (357.9M) | |
| Ebit | (99.8M) | (169.7M) | (213.3M) | (320.1M) | (364.8M) | (346.5M) | |
| Ebitda | (69.7M) | (144.0M) | (186.7M) | (299.4M) | (326.2M) | (309.9M) | |
| Income Before Tax | (146.4M) | (188.8M) | (179.7M) | (278.2M) | (376.1M) | (357.3M) | |
| Net Income | (146.4M) | (169.4M) | (180.1M) | (278.5M) | (111.4M) | (117.0M) | |
| Income Tax Expense | (21K) | (19.4M) | 409K | 313K | 223K | 234.2K | |
| Research Development | 141.0M | 131.8M | 210.3M | 235.8M | 245.0M | 123.1M | |
| Total Revenue | 175.3M | 198.3M | 227.5M | 212.0M | 145.2M | 169.3M | |
| Gross Profit | 170.1M | 192.2M | 220.7M | 204.4M | 133.8M | 163.4M | |
| Cost Of Revenue | 5.2M | 6.1M | 6.8M | 7.6M | 11.5M | 5.9M | |
| Tax Provision | (21K) | (19.4M) | 409K | 313K | 223K | 234.2K | |
| Net Interest Income | (8.8M) | (14.0M) | (18.1M) | (5.0M) | 10.4M | 11.0M | |
| Interest Income | 10.1M | 5.0M | 2.0M | 6.3M | 21.8M | 22.9M |
Travere Therapeutics Key Cash Accounts
Cash flow analysis captures how much money flows into and out of Travere Therapeutics. It measures of how well Travere is doing because it can show the actual money that comes into and out of the Company from sales instead of measuring expenses against revenue to determine earnings. You have to read the cash flow statement in three sections. The first section shows how much money Travere Therapeutics brought in, usually known as net revenue or sales. This is different from earnings because it does not include expenses when determining net revenue for use on this part of the cash flow statement. Next, are operating activities, which show how much money Travere had leftover after paying for its expenses. This number can be calculated in two ways: by subtracting the total of all operating expenses from net revenue or by adding up changes to cash and other assets or liabilities on this part of the statement. The third section is about investing activities, which shows what Travere Therapeutics has done with the money that it received from the sale of assets or what it spent to acquire new ones. This section can be broken down into two parts: investing in existing businesses (in other words, buying more stock) and investing in non-business activities like paying off debt or making acquisitions.
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Change In Cash | (40.4M) | 22.3M | 81.0M | (104.1M) | (3.5M) | (3.3M) | |
| Free Cash Flow | (73.8M) | (162.6M) | (38.9M) | (214.8M) | (322.3M) | (306.2M) | |
| Depreciation | 20.4M | 24.6M | 26.6M | 33.1M | 38.5M | 40.5M | |
| Other Non Cash Items | 2.7M | 102.5M | 23.8M | 19.0M | 39.0M | 41.0M | |
| Capital Expenditures | 15.6M | 119.8M | 24.2M | 28.6M | 668K | 634.6K | |
| Net Income | (146.4M) | (169.4M) | (180.1M) | (278.5M) | (376.3M) | (357.5M) | |
| End Period Cash Flow | 62.4M | 84.8M | 165.8M | 61.7M | 58.2M | 58.0M | |
| Change To Inventory | (2.0M) | (5.1M) | (1.8M) | (2.1M) | (39.4M) | (37.4M) | |
| Investments | 35.4M | 58.5M | (113.5M) | (3.4M) | 36.0M | 37.8M | |
| Change To Netincome | 55.3M | 117.7M | 23.2M | 41.6M | 37.4M | 43.7M |
Travere Financial Ratios Relationships
Comparative valuation techniques use various fundamental indicators to help in determining Travere Therapeutics's current stock value. Our valuation model uses many indicators to compare Travere Therapeutics value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Travere Therapeutics competition to find correlations between indicators driving Travere Therapeutics's intrinsic value. More Info.Travere Therapeutics is rated fourth in return on equity category among its peers. It is rated third in return on asset category among its peers . At this time, Travere Therapeutics' Return On Equity is fairly stable compared to the past year. The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Travere Therapeutics' earnings, one of the primary drivers of an investment's value.Travere Therapeutics Systematic Risk
Travere Therapeutics' systematic risk plays a vital role in portfolio allocation when considering its stock to be added to a well-diversified portfolio. Travere Therapeutics volatility which cannot be eliminated through diversification, requires returns over the risk-free rate. Over the long run, a well-diversified portfolio provides returns that match its exposure to systematic risk. In this case, investors face a trade-off between expected returns and systematic risk and, therefore, can only reduce a portfolio's exposure to systematic risk by sacrificing expected returns on the portfolio.
The output start index for this execution was ten with a total number of output elements of fifty-one. The Beta measures systematic risk based on how returns on Travere Therapeutics correlated with the market. If Beta is less than 0 Travere Therapeutics generally moves in the opposite direction as compared to the market. If Travere Therapeutics Beta is about zero movement of price series is uncorrelated with the movement of the benchmark. if Beta is between zero and one Travere Therapeutics is generally moves in the same direction as, but less than the movement of the market. For Beta = 1 movement of Travere Therapeutics is generally in the same direction as the market. If Beta > 1 Travere Therapeutics moves generally in the same direction as, but more than the movement of the benchmark.
Today, most investors in Travere Therapeutics Stock are looking for potential investment opportunities by analyzing not only static indicators but also various Travere Therapeutics' growth ratios. Consistent increases or decreases in fundamental ratios usually indicate a possible pattern that can be successfully translated into profits. However, when comparing two companies, knowing each company's growth growth rates may not be enough to decide which company is a better investment. That's why investors frequently use static breakdown of Travere Therapeutics growth as a starting point in their analysis.
Price Earnings To Growth Ratio |
|
Travere Therapeutics December 1, 2024 Opportunity Range
Along with financial statement analysis, the daily predictive indicators of Travere Therapeutics help investors to analyze its daily demand and supply, volume, patterns, and price swings to determine the real value of Travere Therapeutics. We use our internally-developed statistical techniques to arrive at the intrinsic value of Travere Therapeutics based on widely used predictive technical indicators. In general, we focus on analyzing Travere Stock price patterns and their correlations with different microeconomic environment and drivers. We also apply predictive analytics to build Travere Therapeutics's daily price indicators and compare them against related drivers.
| Downside Deviation | 2.63 | |||
| Information Ratio | 0.2386 | |||
| Maximum Drawdown | 23.97 | |||
| Value At Risk | (4.13) | |||
| Potential Upside | 11.58 |
Additional Tools for Travere Stock Analysis
When running Travere Therapeutics' price analysis, check to measure Travere Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Travere Therapeutics is operating at the current time. Most of Travere Therapeutics' value examination focuses on studying past and present price action to predict the probability of Travere Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Travere Therapeutics' price. Additionally, you may evaluate how the addition of Travere Therapeutics to your portfolios can decrease your overall portfolio volatility.